-

Forge Biologics to Present at Jefferies Gene Therapy / Editing Summit

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., Forge’s CEO, President, and Co-Founder, will deliver a company presentation at the Jefferies Gene Therapy / Editing Summit on Thursday, October 28, at 12:30 p.m. ET.

The conference will take place October 27-28, 2021 virtually. A live replay of the presentation will be available on the Jefferies conference website for 30 days following the presentation: https://wsw.com/webcast/jeff208/forge/1993455.

The Forge Biologics leadership team, including Dr. Miller; John Maslowski, Chief Commercial Officer; Christina Perry, Vice President of Finance and Investor Relations; and Magdalena Tyrpien, Vice President and Head of Business Development, will be available for 1:1 meetings virtually throughout the conference.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Forge Biologics


Release Summary
Forge Biologics to Present at Jefferies Gene Therapy Editing Summit
Release Versions
Hashtags

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Avista Therapeutics and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

PITTSBURGH & COLUMBUS, Ohio--(BUSINESS WIRE)--Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, and Forge Biologics, (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene...

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help...

Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ pl...
Back to Newsroom